» Articles » PMID: 32273676

Factors Affecting Compliance to Anti-Vascular Endothelial Growth Factor Treatment of Diabetic Macular Edema in a Cohort of Jordanian Patients

Abstract

Purpose: To determine compliance rates and characteristics and to investigate factors affecting patients' adherence to treatment with anti-vascular endothelial growth factors (anti-VEGFs) for diabetic macular edema (DME) in a cohort of Jordanian patients.

Methods: A retrospective case series wherein the files of DME patients treated with anti-VEGFs were reviewed and analyzed for factors affecting treatment compliance was undertaken. Demographic, clinical and ocular characteristics were recorded. All patients were also interviewed by phone using a structured questionnaire. Univariate and multivariate analyses were performed to determine factors associated with compliance.

Results: A total of 117 patients (65 males 52 females) were included in this study with a mean age of 62.93 years (±9.75). Approximately, 85% of patients were compliant to their treatment and follow-up plan during the first year of management. Subjective perception of visual improvement after receiving three loading doses was the only independent variable with a unique statistically significant contribution to compliance. All other studied factors in this group of patients were not significantly associated with patient compliance.

Conclusion: VEGF suppression via the intravitreal route to treat DME is a long-term process that requires caregiver dedication but also proper patient compliance. Addressing real-life barriers in those patients may help guide future strategies to improve the treatment experience, lower the financial burden and contribute to better outcomes. Patients' perceptions of possible treatment outcomes at the short term may influence their long-term commitment to therapy.

Citing Articles

Factors Influencing Treatment Preference in Patients with Diabetic Macular Edema: A Study Using Conjoint Analysis.

Hirano T, Tanabe K, Murata T Ophthalmol Ther. 2024; 13(11):2887-2901.

PMID: 39287765 PMC: 11493937. DOI: 10.1007/s40123-024-01026-6.


Factors Affecting Compliance and Visual Outcomes in Patients Receiving Intravitreal Bevacizumab Injections.

Radhakrishnan O, Agrawal T, Giri N, Gandhi S, Goyal K Cureus. 2024; 16(8):e66760.

PMID: 39268278 PMC: 11391661. DOI: 10.7759/cureus.66760.


Non-adherence and non-persistence to intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy: a systematic review and meta-analysis.

Shahzad H, Mahmood S, McGee S, Hubbard J, Haque S, Paudyal V Syst Rev. 2023; 12(1):92.

PMID: 37269003 PMC: 10237080. DOI: 10.1186/s13643-023-02261-x.


Determination of Factors Influencing the Health Belief Model (HBM) and Adherence to Intravitreal Anti-vascular Endothelial Growth Factor (VEGF) Among Patients With Diabetic Macular Edema (DME).

Ting Yih Ling J, Mohd Zain A, Naffi A, Mustapha M, Wan Abdul Halim W Cureus. 2023; 15(2):e34669.

PMID: 36909105 PMC: 9993440. DOI: 10.7759/cureus.34669.


Real-World Outcomes of Anti-VEGF Therapy in Diabetic Macular Oedema: Barriers to Treatment Success and Implications for Low/Lower-Middle-Income Countries.

Sam-Oyerinde O, Patel P Ophthalmol Ther. 2023; 12(2):809-826.

PMID: 36821027 PMC: 10011234. DOI: 10.1007/s40123-023-00672-6.


References
1.
Weiss M, Sim D, Herold T, Schumann R, Liegl R, Kern C . COMPLIANCE AND ADHERENCE OF PATIENTS WITH DIABETIC MACULAR EDEMA TO INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY IN DAILY PRACTICE. Retina. 2017; 38(12):2293-2300. DOI: 10.1097/IAE.0000000000001892. View

2.
Fong D, Luong T, Contreras R, Jimenez J, Custis P, Patel V . TREATMENT PATTERNS AND 2-YEAR VISION OUTCOMES WITH BEVACIZUMAB IN DIABETIC MACULAR EDEMA: An Analysis From a Large U.S. Integrated Health Care System. Retina. 2017; 38(9):1830-1838. PMC: 6110373. DOI: 10.1097/IAE.0000000000001790. View

3.
Ross E, Hutton D, Stein J, Bressler N, Jampol L, Glassman A . Cost-effectiveness of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema Treatment: Analysis From the Diabetic Retinopathy Clinical Research Network Comparative Effectiveness Trial. JAMA Ophthalmol. 2016; 134(8):888-96. PMC: 6648661. DOI: 10.1001/jamaophthalmol.2016.1669. View

4.
. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology. 2008; 115(9):1447-9, 1449.e1-10. PMC: 2748264. DOI: 10.1016/j.ophtha.2008.06.015. View

5.
Lima L, Zweifel S, Engelbert M, Sorenson J, Slakter J, Cooney M . Evaluation of safety for bilateral same-day intravitreal injections of antivascular endothelial growth factor therapy. Retina. 2009; 29(9):1213-7. DOI: 10.1097/IAE.0b013e3181b32d27. View